Repligen Corp (RGEN)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- Ticker
- RGEN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $9.84B
- 52-week range
- $100.99 - $198.87
Valuation
- Share price
- $173.49 (close of Nov 6, 2026)
- P/E (TTM)
- -867.45x
- Price to book
- 4.70x
- Price to free cash flow
- 92.16x
- Enterprise value
- $9.80B
- Book value per share
- $36.90
Price performance
| Period | Change |
|---|---|
| 1 day | +2.97% |
| 5 days | -1.95% |
| 1 month | -0.78% |
| 3 months | +8.81% |
| 6 months | +37.95% |
| Year to date | +5.88% |
| 1 year | +19.66% |
| 3 years | +20.52% |
| 5 years | -34.98% |
| 10 years | +540.89% |
| All time | +1,442.13% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 11.28%
- Shares short
- 7.15M
- Days to cover
- 4.88
- Change since prior report
- -5.76%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed RGEN trades
Lisa McClain · Jefferson Shreve
Super investors holding RGEN
Lee Ainslie (Maverick Capital LTD) · Ken Griffin (Citadel) · Stanley Druckenmiller (Duquesne Family Office) · Wallace Weitz (Weitz Investment Management)
Profitability and growth
- Return on equity
- 2.32%
- Return on invested capital
- 1.49%
- Return on assets
- 1.66%
- Return on capital employed
- 1.96%
- Gross margin
- 52.32%
- Net margin
- 6.62%
- EBITDA margin
- 18.14%
- Revenue growth
- 16.36%
- Free cash flow growth
- -37.28%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 1.09%
- Current ratio
- 9.88x
- Net debt to EBITDA
- -0.27x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $738.26M
- Cost of revenue
- $352.01M
- Gross profit
- $386.25M
- EBITDA
- $133.91M
- Net income
- $48.89M
- Earnings per share
- $0.87
- Research and development
- $54.18M
- Interest expense
- $21.51M
- Shares outstanding
- 56.23M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $738.26M | $386.25M | $48.89M | $0.87 |
| 2024-12-31 | $634.44M | $274.64M | -$25.51M | -$0.46 |
| 2023-12-31 | $632.36M | $278.44M | $35.60M | $0.64 |
| 2022-12-31 | $801.54M | $455.71M | $185.96M | $3.35 |
| 2021-12-31 | $670.53M | $391.25M | $128.29M | $2.33 |
| 2020-12-31 | $366.26M | $209.63M | $59.93M | $1.14 |
| 2019-12-31 | $270.25M | $151.15M | $21.41M | $0.44 |
| 2018-12-31 | $194.03M | $107.50M | $16.62M | $0.38 |
| 2017-12-31 | $141.24M | $74.19M | $28.35M | $0.74 |
| 2016-12-31 | $104.54M | $57.42M | $11.68M | $0.35 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 52.32% | 6.62% | 2.32% | 1.49% |
| 2024-12-31 | 43.29% | -4.02% | -1.29% | -1.26% |
| 2023-12-31 | 44.03% | 5.63% | 1.81% | 0.99% |
| 2022-12-31 | 56.85% | 23.20% | 9.73% | 8.21% |
| 2021-12-31 | 58.35% | 19.13% | 7.33% | 6.71% |
| 2020-12-31 | 57.23% | 16.36% | 3.92% | 3.87% |
| 2019-12-31 | 55.93% | 7.92% | 2.02% | 2.37% |
| 2018-12-31 | 55.40% | 8.56% | 2.70% | 2.94% |
| 2017-12-31 | 52.53% | 20.07% | 4.79% | 2.03% |
| 2016-12-31 | 54.93% | 11.17% | 6.92% | 6.05% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $767.63M | $542.21M |
| 2024-12-31 | $757.36M | $525.57M |
| 2023-12-31 | $751.32M | $510.14M |
| 2022-12-31 | $523.46M | - |
| 2021-12-31 | $603.81M | - |
| 2020-12-31 | $717.29M | - |
| 2019-12-31 | $528.39M | $232.77M |
| 2018-12-31 | $193.82M | - |
| 2017-12-31 | $173.76M | $99.25M |
| 2016-12-31 | $141.78M | $95.27M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $93.90M | $32.60M |
| 2024-12-31 | $149.72M | $48.07M |
| 2023-12-31 | $77.70M | $25.57M |
| 2022-12-31 | $87.25M | $27.32M |
| 2021-12-31 | $51.93M | $27.50M |
| 2020-12-31 | $40.17M | $17.01M |
| 2019-12-31 | $48.71M | $12.85M |
| 2018-12-31 | $22.14M | $10.19M |
| 2017-12-31 | $12.00M | $6.75M |
| 2016-12-31 | $3.20M | $4.59M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-27 | Sep 2026 | $0.46 |
| 2026-07-28 | Jun 2026 | $0.45 |
| 2026-05-05 | Mar 2026 | $0.38 |
| 2026-02-24 | Dec 2025 | $0.44 |
| 2025-10-28 | Sep 2025 | $0.42 |
| 2025-07-29 | Jun 2025 | $0.40 |
| 2025-04-29 | Mar 2025 | $0.35 |
| 2025-02-20 | Dec 2024 | $0.41 |
Filings and sources
- Company website
- repligen.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Teleflex Inc (TFX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Avantor, Inc. (AVTR) · Baxter International Inc (BAX) · Solventum Corp (SOLV) · West Pharmaceutical Services Inc (WST) · Alcon Inc (ALC)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades